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The complicated, evolving landscape of cancer mutations poses a formidable challenge to identify 
cancer genes among the large lists of mutations typically generated in NGS experiments. The ability to 
prioritize these variants is therefore of paramount importance. To address this issue we developed 
OncoScore, a text-mining tool that ranks genes according to their association with cancer, based on 
available biomedical literature. Receiver operating characteristic curve and the area under the curve 
(AUC) metrics on manually curated datasets confirmed the excellent discriminating capability of 
OncoScore (OncoScore cut-off threshold = 21.09; AUC = 90.3%, 95% CI: 88.1-92.5%), indicating that 
OncoScore provides useful results in cases where an efficient prioritization of cancer-associated 
genes is needed. 
 
 
Introduction 
The huge amount of data emerging from NGS projects is bringing a revolution in molecular medicine, 
leading to the discovery of a large number of new somatic alterations that are associated with the 
onset and/or progression of cancer. However, researchers are facing a formidable challenge in 
prioritizing cancer genes among the variants generated by NGS experiments. Despite the 
development of a significant number of tools devoted to cancer driver prediction, limited effort has 
been dedicated to tools able to generate a gene-centered Oncogenic Score based on the evidence 
already available in the scientific literature. To overcome these limitations, we propose here 
OncoScore, a bioinformatics text-mining tool capable of automatically scanning the biomedical 
literature by means of dynamically updatable web queries and measuring gene-specific cancer 
association in terms of gene citations. The output of this analysis is a score representing the strength 
of the association of any gene symbol to cancer, based on the literature available at the time of the 
analysis. OncoScore is distributed as a R Bioconductor package 
(https://bioconductor.org/packages/release/bioc/html/OncoScore.html) in order to allow full 
customization of the algorithm and easy integration in existing NGS pipelines, and as a web tool for 
easy access by researchers with limited or no experience in bioinformatics 
(http://www.galseq.com/oncoscore.html). 
 
Results 
We analyzed the performance of OncoScore on the Cancer Genes Census (CGC; Supplementary 
Tab. 1), a collection of regularly updated and manually annotated genes accepted as causally 
implicated in oncogenesis 1. To assess the ability of OncoScore to discriminate between cancer and 
non-cancer genes we generated the OncoScore estimation for the whole CGC dataset and for a 
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manually curated list of genes not associated with cancer (named nCan; Supplementary Tab. 2; see 
Methods section for further details). Genes with a total citation count < 10 publications were filtered 
out, therefore from a total of 507 CGC and 302 nCan, 472 (93.1%) and 266 (88.1%) genes were 
further processed.  
 
OncoScore performance 
The distribution of OncoScore values differed significantly between the two groups (mean: 48.8 and 
14.8 for CGC and nCan, respectively; p-value = 2.2e-16; Fig. 1a-b). The receiver operating 
characteristic (ROC) curve and the area under the curve (AUC) metrics (Fig. 2a-b) confirmed the 
excellent capability of OncoScore in discriminating the true positive from the true negative cancer 
genes at different cut-off values (OncoScore cut-off threshold = 21.09; AUC1 = 90.3%, 95% CI: 88.1-
92.5; see Methods section for further details). The same analysis performed on the entire list of known 
human genes (Supplementary Tab. 3) using an identical cut-off (21.09) identified a total of 5945 
cancer-related genes, corresponding to 35% of the total (Suppl. Fig. 1). 
 
Comparative analysis 
The results obtained by OncoScore were then compared with those of Gene Ranker 
(http://cbio.mskcc.org/tcga-generanker/) 2, a web tool extensively used to estimate the oncogenicity of 
putative cancer genes. Gene Ranker assigns a cancer score to each gene according to a complex set 
of fixed properties (details can be found at: http://cbio.mskcc.org/tcga-generanker/sources.jsp), where 
the score associated with each gene is based on the confidence of the data used to generate the 
prediction, therefore, from a functional point of view OncoScore and Gene Ranker are very similar. To 
compare the performance of the two approaches we generated the Gene Ranker ROC curve and we 
calculated the AUC metric (AUC2 = 85.98%, 95% CI: 0.8337-0.886). Gene Ranker was able to score 
452/507 (89.2%) CGC and 294/302 (97.4%) nCan genes for a total of 746 out of 809 genes. Globally, 
OncoScore showed greater AUC (AUC1 > AUC2) than Gene Ranker (see Methods section for further 
details). Notably, a significant number of well-known oncogenes/oncosuppressors, such as ASXL1, 
SETBP1, TET2, SF3B1 and SRSF1 received an extremely low Gene Ranker score (< 0.250) or were 
not classified at all, which is probably explained by the use of time-fixed scoring criteria (Fig. 1c-d).  
 
Chronic myeloid leukemia 
Subsequently, we tested OncoScore on real NGS data obtained from patients affected by Chronic 
Myeloid Leukemia (CML). CML originates as an indolent disease with limited aggressiveness (chronic 
phase, CP). However, if left untreated, it invariably progresses to a final, aggressive phase known as 
blast crisis (BC). The CML-CP is causally associated with the Breakpoint Cluster Region (BCR) and 
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Abelson (ABL) gene fusion (BCR-ABL) 3,4. The presence of the BCR-ABL fusion is necessary and 
sufficient to generate the leukemic phenotype, therefore a very limited number of oncogenic variants 
besides BCR-ABL are expected to be present in CP at diagnosis, at least in the predominant clone. In 
addition, since CML is a disease affecting mostly old people, CML-CP cells are expected to carry a 
significant number of passenger variants 5. Conversely, evolution towards BC is caused by a set of 
only partially characterized oncogenic variants responsible for the impairment of the myeloid 
differentiation machinery 6. BC evolution usually occurs within 2-3 years after the onset of the disease, 
hence the accumulation of passenger variants during the evolution from CP to BC is limited. 
Therefore, in CML the number of somatic mutations functionally associated to cancer is expected to 
be higher in BC than in CP.  
To test OncoScore, we generated whole-exome sequencing data on 33 Chronic Myeloid Leukemia 
patients, 23 in Chronic Phase and 10 in Blast Crisis. In order to selectively identify somatic mutations, 
CP was filtered against the germline exome data, while BC was filtered against the corresponding CP 
exome (see Methods section for further details). A total of 107 and 34 nonsynonymous somatic 
variants were identified in CP and BC, respectively (Supplementary Tab. 4). All the variants were 
validated by Sanger sequencing in case and control samples. The OncoScore estimation was 
subsequently performed for all the 141 Sanger-validated somatic variants (Supplementary Tab. 4): the 
score of the BC associated variations was higher than that of CP (mean OncoScore = 35.6 ± 4.91 
SEM and 19.2 ± 2.07 SEM for BC and CP, respectively; p=0.0007; Fig. 3). Manual inspection of the 
top 10 BC OncoScore genes (Supplementary Tab. 5) highlighted the presence of at least 5 genes 
(ABL1, NRAS, ASXL1, RUNX1, IKZF1) that are functionally associated with CML progression 7,8, 
suggesting that OncoScore was able to correctly prioritize biologically relevant CML cancer genes.  
 
OncoScore analysis of large structural variations 
Large deletions and amplifications are among the most frequent structural variations occurring during 
carcinogenesis. Unfortunately, the identification of the underlying oncogenes/oncosuppressors is very 
challenging. The reason is that the size of the structural variants is often in the range of the 
megabases, therefore involving a large number of genes. To allow a fast and efficient prioritization of 
driver genes involved in large copy-number abnormalities, OncoScore is able to process chromosomal 
regions as query input and to output a list of all the genes present in the input region, together with the 
associated OncoScore. This allows to quickly verify if some of the genes involved in the structural 
variation can play an important role in cancer onset/evolution. To test this feature we analyzed three 
regions (Supplementary Table 6), 8p21, 10q23 and 12p13, known to be recurrently deleted in prostate 
cancer 9,10. Manual analysis of the literature indicates that NKX3.1, PTEN and CDKN1B are important 
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oncosuppressors that are lost upon deletion of the 3 loci 9-13 and are known to play a driver role in 
prostate cancer evolution.  
For the sake of keeping the analysis focused on the genes with the highest driver potential, we initially 
removed all the events with an OncoScore of 0 and then we selected those with an OncoScore 
estimation above the 90th percentile. Overall, OncoScore analysis of the 8p21 region revealed the 
presence of a total of 106 events. Of them 74 had an OncoScore > 0 and 47 an OncoScore ≥ 21. A 
total of 8 cancer genes with an OncoScore above the 90th percentile was identified (TNFRSF10B, 
TNFRSF10C, TNFRSF10A, TNFRSF10D, LZTS1, NKX3-1, BNIP3L and RHOBTB2; OncoScore 
range: 71.4-86.3). The same analysis done on the 10q23 deletion identified a total of 124 events, 69 
with an OncoScore > 0, 39 with OncoScore > 21 and 7 above the 90th percentile (PTEN, KLLN, 
SNCG, TNKS2, CEP55, PLCE1 and HELLS; OncoScore range: 50.6-74.1). A total of 256 events was 
identified in the 12p13 locus. Of them 141 had an OncoScore > 0 and 85 an OncoScore ≥ 21. A total 
of 14 cancer genes with an OncoScore above the 90th percentile was identified (ETV6, TNFRSF1A, 
ING4, CDKN1B, MIR200C, LTBR, FOXM1, GPRC5A, KDM5A, TIGAR, PRB2, CCND2, RAD51AP1 
and KLRK1; OncoScore range: 59.1-86.7).  
Notably, the 3 known driver genes, NKX3.1, PTEN and CDKN1B, were all present in the OncoScore 
list, ranking 6th, 1st and 4th, respectively. Moreover, several other genes present in the OncoScore lists, 
such as KLLN, LZTS1, BNIP3L, ING4 as well as MIR200C microRNA were recently implicated in the 
development of prostate cancer 14-18. Taken globally these data indicate that OncoScore is a useful 
prioritization tool for the annotation of copy-number abnormalities in human cancer.  
 
Time-series plot 
Given the strong impulse generated by NGS to cancer research, it is not uncommon that a gene 
previously considered ‘non-cancer’ subsequently turns-out to be a driver. The OncoScore of a newly 
discovered cancer gene will start increasing over time, as its oncogenic role is confirmed by 
subsequent studies. This process, however, requires a significant amount of time, causing a potential 
delay between the identification of the oncogene and the acquisition of a ‘driver’ OncoScore 
annotation. To facilitate the identification of recently discovered cancer genes we implemented a time-
series function (perform.time.series.query) which allows plotting the OncoScore through a user-
defined time-window. To test this function, we generated time-series queries spanning from 1975 to 
2016 (Fig. 4) and involving two different dataset: 1) a set of manually defined cancer genes (TP53, 
KRAS, NRAS, HRAS, ASXL1, IDH1, IDH2, TET2, SETBP1) as well as the housekeeping genes 
GAPDH and GUSB; 2) a set of 10 genes randomly extracted from the CGC (ARID1A, HMGA2, KIF5B, 
NUP214 and RBM15) and nCan (ALMS1, DCAF17, GPD1L, WFS1 and RBM10) lists. In dataset 1, at 
the final time point (2016), all the cancer genes under analysis scored > 60, while the two 
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housekeeping reached a plateau at ~20. The dynamics of the OncoScore pattern revealed the 
presence of 2 cancer gene clusters: the first one comprising oncogenes/oncosuppressors identified in 
the 1985-94 decade (TP53 and the RAS family), right after the development of the PCR by Kary Mullis 
19 and just a few years after the invention of the ‘Sanger’ sequencing technique by Frederick Sanger 
20; the second one occurring right after the NGS breakthrough and comprising ASXL1, IDH1/2, TET2 
and SETBP1. In particular, the behavior of SETBP1 curve is interesting, because it reflects the 
complex story of SETBP1 discovery. SETBP1 was initially identified as an oncogene (NUP98-SETBP1 
fusion) in pediatric acute T-cell lymphoblastic leukemia by Panagopoulos and colleagues 21, which 
explains the first, sharp increase in SETBP1 OncoScore back in 2007. Subsequently, in January 2010, 
Cristobal and colleagues 22 demonstrated SETBP1 overexpression as a novel leukemogenic 
mechanism in acute myeloid leukemia. Their finding is represented as a second peak in the SETBP1 
time-series. Their finding was shortly followed by a seminal publication by Hoischen and colleagues 23 
where the authors demonstrated that de novo, germline SETBP1 mutations were responsible for the 
onset of the Schinzel-Giedion syndrome (SGS), a severe disorder characterized by severe mental 
retardation, distinctive facial features and multiple congenital malformations. Given that this finding 
doesn’t directly associate SETBP1 with cancer, this led to a decrease in the overall SETBP1 score, 
because in the period between 2010 and 2013 a number of papers confirming the link between 
SETBP1 and SGS (and therefore counting as negative for the OncoScore) appeared in the literature. 
Despite this decrease however, SETBP1 score never fell below the OncoScore cut-off threshold, 
therefore remaining in the cancer-associated genes group. Finally, in 2013 we 24 and others 25,26 
demonstrated the occurrence of somatic, oncogenic SETBP1 point mutations in several types of 
cancer, which caused a new increase in the overall SETBP1 OncoScore. In the second dataset all the 
CGC genes (5/507) were classified as oncogenes by OncoScore and 4 (4/302) out of 5 nCan genes 
(ALMS1, DCAF17, GPD1L and WFS1) were classified as ‘non-cancer’ at the final time point, as 
expected. The remaining nCan gene (1/302), RBM10, showed an interesting behavior, as its 
OncoScore remained close to 0 until 2010-2011, where it arose abruptly to over 40. Manual analysis 
of the literature showed a very recent association of this gene with cancer 27-29, which highlights the 
usefulness of the OncoScore analysis in order to identify recently discovered cancer-associated 
genes.  
 
 
Discussion 
The progress of genomic-scale sequencing allows the analysis of cancer genomes at an 
unprecedented resolution, significantly increasing our ability to study the mechanisms underlying 
cancer onset and progression. Many issues remain however to be solved in order to transform an 
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apparently meaningless list of mutated genes into useful information. One of these issues is 
represented by the ability to differentiate genes with oncogenic potential involved in the early stages of 
neoplastic transformation from passenger mutations. Both are present in the majority of tumor cells 
being analyzed; therefore differences in mutation frequencies cannot be utilized here. Despite 
dramatic progresses in sequencing technologies, a systematic, painfully slow manual analysis of 
cancer literature remains the main approach by which biomedical researchers try to assess the 
oncogenicity of genes identified in cancer samples and to prioritize them. In this study, we proposed a 
new method aimed at quickly identifying cancer-associated genes through automated PubMed queries 
and dedicated text-mining algorithms. To perform PubMed queries we took advantage of the public 
API to the NCBI Entrez system: the NCBI E-utilities (http://www.ncbi.nlm.nih.gov/books/NBK25500/).  
By comparing OncoScore with Gene Ranker we demonstrated that our tool has better discriminating 
capabilities than the latter.  
At present, possible issues affecting OncoScore are:  
1) Analysis of genes with a very limited number of bibliographic references: limited data-mining 
information represents a significant issue, because it causes a significant loss of classification power. 
Therefore, under standard OncoScore settings, genes with less than 10 references are not 
considered. This problem is mitigated by the accumulation of new data causing the number of genes 
with limited or no bibliographic references to shrink over time.  
2) A query error can occur because of the presence of ‘ambiguous’ gene names. Indeed, HGNC 
names would be preferable over gene symbols given their uniqueness. Unfortunately PubMed expects 
gene symbols in standard queries and doesn’t allow the use of symbol tags. Given the process of 
gene symbol definition, a minimal fraction of ambiguous cases is therefore unavoidable when using 
symbols as the primary input. To limit this potential issue however, OncoScore will allow the end-user 
to: 1) directly input GeneID numbers instead of symbols; 2) automatically check if a gene symbol is 
ambiguous and to prompt an alert in order to allow the end-user to disambiguate it. 
3) Another problem may exist for genes falling in the uncertainty region close to the optimal cut-off 
value (21.09). For instance, housekeeping genes such as GAPDH (OncoScore: 23.29) and GUSB 
(OncoScore: 20.53) fall within this group. These genes are often cited in cancer biological studies as 
reference genes used for normalization, which suggests that categorization of genes with an 
OncoScore close to the threshold should be interpreted with caution. 
 
Conclusions 
In this work we presented OncoScore, a bioinformatics data mining tool dedicated to the assessment 
of the oncogenic potential of genes. OncoScore performance improved the state-of-the-art on 
manually curated datasets, therefore it could be useful in all cases where an efficient differentiation 
 8 
 
between potential drivers and passenger genes is needed. The strategy used to implement 
OncoScore allows the model to be continuously up to date, easy to use and executable in real-time. 
OncoScore analysis on real NGS variant data as well as on chromosomal regions shows the utility of 
this tool in the crucial task of cancer gene prioritization. The identification of genes causally involved in 
cancers pathogenicity will be greatly helped by OncoScore, although the final assignment of a driver 
gene to an individual cancer will require further information such as the histological type and the 
expression level of the mutated gene as well as information on the functional effect of the mutation. 
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Methods 
 
Gene Datasets 
The CGC dataset was collected from the Cancer Gene Census (CGC; version: November 2013; 
http://www.sanger.ac.uk/science/data/cancer-gene-census) database, a set of genes causally 
implicated in cancer. The CGC (November 2013) accounts for 507 cancer-associated genes. The not-
CGC (nCan) were collected from the GeneCards database and represent a set of genes not 
previously involved in the onset and in the progression of neoplastic diseases although they may be 
involved in human genetic and syndromic diseases. nCan were manually selected from a list of genes 
downloaded from Gene Cards (Release 3.10) according to the Gene Cards description.  
 
Data Sources 
Gene citations, used as control, and cancer related genes citations from biomedical literature were 
retrieved from PubMed repository. PubMed is a freely accessible web search engine developed and 
maintained by the National Center for Biotechnology Information (NCBI) at the National Institutes of 
Health (NIH) and it is updated daily. PubMed accounts for more than 24 million citations of biomedical 
literature from MEDLINE (http://www.ncbi.nlm.nih.gov/pubmed), from life science journals and from 
online books. The citations were retrieved from PubMed by using a set of R scripts developed 
according to the Entrez Programming Utilities (E-utilities) 30. The E-utilities are an interface to the 
Entrez system, which includes many databases covering a variety of biomedical data such as the 
biomedical literature.  
 
Text Mining: Keywords search terms and syntax queries 
In order to retrieve the citation counts, dedicated text-mining R scripts were developed based on 
optimized keywords. The genes citations numbers were searched by the gene symbols while the 
cancer genes citations were searched by the gene symbols associated with the following keywords 
search terms “(lymphoma or tumor or neoplasm or malignancy or cancer or leukemia)”. The aim of 
such a set of keywords is to give a comprehensive definition of the topic in order to retrieve all the 
articles concerning cancer research. In both cases, the search terms were processed according to the 
“Automatic Term Mapping”, a process used by PubMed to find a match to unqualified terms that are 
entered into the search field. Untagged terms are matched (in this order) against subjects using the 
MeSH (Medical Subject Headings) translation table, journals using the Journals translation table, and 
authors and investigators, using the the Full Author translation table, Author index, Full Investigator 
translation table and Investigator index. If a match is found in any translation table, the mapping stops. 
When subject or journal matches are found, the query and individual terms are also searched in All 
Fields. If no match is found in any tables, terms are searched in All Fields and ANDed together (see 
https://www.nlm.nih.gov/bsd/disted/pubmedtutorial/020_040.html).  
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The OncoScore Analysis 
The OncoScore analysis consists of a main module aimed at assessing the oncogenic potential of 
genes. It makes use of the citations retrieved from the literature to calculate the score and to classify 
genes with the aim of discriminating cancer from not-cancer putative genes.  
 
OncoScore Definition 
OncoScore is a measure (i.e. a score) of association of genes with cancer based on gene citation 
frequency from biomedical literature, here labelled ࡯࢏࢚ࡳࢋ࢔ࢋ, and gene citation frequency linked to 
cancer, labelled ࡯࢏࢚ࡳࢋ࢔ࢋ	࡭ࡺࡰ	࡯ࢇ࢔ࢉࢋ࢘. The OncoScore is defined to be directly proportional to the 
percentage of gene cancer citations, labelled  ࡼࢋ࢘ࢉ࡯࢏࢚, as (1) ࡼࢋ࢘ࢉ࡯࢏࢚ = ࡯࢏࢚ࡳࢋ࢔ࢋ	࡭ࡺࡰ	࡯ࢇ࢔ࢉࢋ࢘࡯࢏࢚ࡳࢋ࢔ࢋ ∙ ૚૙૙. From 
this, OncoScore is defined as (2) ࡿࢉ࢕࢘ࢋ = ࡼࢋ࢘ࢉ࡯࢏࢚ − ࢻ ∙ ࡼࢋ࢘ࢉ࡯࢏࢚ where ࢻ > ૙ and it is weighted for 
the gene citation value (3) ࢻ = ૚ࡸ࢕ࢍ૛ሺ࡯࢏࢚ࡳࢋ࢔ࢋሻ where ࡯࢏࢚ࡳࢋ࢔ࢋ > ૚. So, the OncoScore is computed as 
follow (4): 
 
ܱ݊ܿ݋ܵܿ݋ݎ݁ = 		 ࡯࢏࢚ࡳࢋ࢔ࢋ	࡭ࡺࡰ	࡯ࢇ࢔ࢉࢋ࢘࡯࢏࢚ࡳࢋ࢔ࢋ ∙ ૚૙૙ −
૚
ࡸ࢕ࢍ૛ሺ࡯࢏࢚ࡳࢋ࢔ࢋሻ ∙
࡯࢏࢚ࡳࢋ࢔ࢋ	࡭ࡺࡰ	࡯ࢇ࢔ࢉࢋ࢘
࡯࢏࢚ࡳࢋ࢔ࢋ ∙ ૚૙૙. 
 
The OncoScore is, hence, based on the number of PubMed articles in which both the gene symbol 
and the cancer keywords appear in the same article, weighted for the logarithmic gene citation number 
as defined above.  
 
The OncoScore discriminative power was assessed on CGC (Supplementary Tab. 1) and nCan 
(Supplementary Tab. 2) datasets. The OncoScore distribution among CGC and aCan genes was 
assessed by Mann-Whitney-Wilcoxon Test and visualized by boxplot (Fig. 1a-b).  
 
OncoScore Classifier 
In order to identify a general discriminating model based on the current information available from the 
literature, we tested different automated classifiers trained on the panels of CGC and nCan genes. 
Specifically, we adopted classifiers built by Linear Discriminant Analysis (LDA) and Logit analysis 
(LOGIT) to select an optimal model in terms of classification accuracy that we dubbed OncoScore 
classifier model. The CGC and not-CGC genes were used to model the probabilities of binary 
outcomes as a function of the OncoScore by using linear discriminant and logistic functions in the 
presence of two classes of categorical data, i.e. oncogene vs not-oncogene. The best prediction 
accuracy, 84.96% (ACC1), was achieved at the optimal OncoScore cut-off equal to 21.09, obtained 
both by Youden’s and top left corner methods 31 (sensitivity 89.32%; specificity 77.78%; Fig. 2a,b). 
 
OncoScore Classifier assessment 
The CGC and nCan genes were analyzed to compare OncoScore results with Gene Ranker. The best 
Gene Ranker discriminating threshold for CGC and nCan was calculated considering the best 
between the Youden’s and top left threshold by maximizing the classification accuracy. Then, cancer 
associated and non-associated genes were discriminated according to the best Gene Ranker 
threshold. The accuracy, sensitivity and sensibility were inferred at the optimal threshold and they 
were compared to the best OncoScore discriminating model.  
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Time Series OncoScore Profile 
The Time Series OncoScore analysis computes scores over time by making use of the citations from 
the literature at different time points. The dynamic score aims to model the association of genes to 
cancer over time, following the evolution of the literature in order to assess the trend to which the 
OncoScore tended to move. The citations over the time series are retrieved by automatically 
performing data mining queries at various time points.  
 
Patients Samples 
A total of 23 CP-CML and 10 BC patients were analyzed. Mononuclear cells were collected at 
diagnosis from bone marrow using Ficoll density gradient centrifugation (tumor sample, CP-CML) and 
peripheral blood or bone marrow mononuclear cells were collected after achievement of Complete 
Cytogenetic Remission (control sample). For BC samples, mononuclear cells were collected at the 
time of progression using Ficoll density gradient centrifugation (BC-CML). For those patients who 
never achieved CCyR, normal lymphocytes were expanded in vitro with IL-2 and phytohemagglutinin, 
as previously published 24. Informed consent was obtained from all subjects. Experimental protocols 
were approved by the University of Milano-Bicocca institutional committee. All methods were 
performed in accordance with relevant guidelines and regulations. 
 
Whole Exome Sequencing 
Genomic DNA (gDNA) was extracted from purified cells with PureLink Genomic DNA kit (Life 
Technologies-Thermo Fisher). Two micrograms of gDNA were sheared to a size of 200-300bp using a 
Bioruptor NextGen Sonicator (Diagenode) and processed according to the standard Illumina protocol. 
The Illumina TruSeq Exome Enrichment kit was used to enrich the genomic libraries for the exonic 
regions. Matched exome libraries of tumor and non-tumor DNA were prepared by Illumina TruSeq 
DNA Sample Preparation Kit and Illumina TruSeq exome enrichment kit by using a standard protocol. 
All the captured DNA libraries were sequenced on an Illumina HiSeq 2500 or a Genome Analyser IIx 
in paired-end mode to yield 76bp sequencing reads.  
 
Base Calling and Sequence alignment 
Base calling and quality control were executed on the Illumina RTA sequence analysis pipeline 
(Illumina). Paired Fastq files were aligned to the human reference genome (GRCh37/hg19) with the 
Burrows–Wheeler-based BWA alignment tool 32 using the BWA-MEM algorithm. Duplicated reads 
were excluded from the analysis using Samblaster. Quality of the aligned reads, somatic variant 
calling and copy number analysis were performed using CEQer2, an in-house evolution of CEQer tool 
33 as previously described 24,34. Splicing variants were analyzed using SpliceFinder 35. Variants were 
annotated using dbSNP146. All the filtered variants, exported as vcf files, were annotated using 
Annovar 36 and manually inspected. 
Variants present in less than 35% of the tumor reads were filtered-out, in order to specifically isolate 
the variants present in the major clone. All the candidate somatic mutations identified by WES were 
then re-confirmed by Sanger sequencing. 
 
Validation of mutations by Sanger sequencing 
Variant DNA was amplified by PCR (FastStart High Fidelity PCR system, Roche Applied Science, 
Germany) and the amplicons of tumor and normal DNA were processed for Sanger sequencing at 
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GATC (GATC Biotech AG, Cologne, Germany). The presence of each substitution was confirmed by 
using Chromas platform (Technelysium).  
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Fig. 1. OncoScore distribution of ‘Cancer’ and ‘Non-Cancer’ gene sets. BoxPlot (a) and frequency 
histogram (b) of the OncoScore distributions for non-cancer and cancer genes. (a) Each box plot is 
drawn between the lower and upper quartiles of the distributions with bold black line showing the 
median value. The OncoScore distributions of ‘Cancer’ and ‘Non-Cancer’ genes are significantly 
different (Mann-Whitney-Wilcoxon Test: p-value = 2.2e-16). b) OncoScore frequency distribution 
plotted by equispaced breaks. c) OncoScore and d) Gene Ranker ranking plot of a mixed panel 
comprising ‘Cancer’ (*) and ‘Non-Cancer’ genes. The horizontal red lines identify the best cut-off 
classifier threshold models.  
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Fig. 2. a) OncoScore prediction accuracy. ROC curve depicting the relationship between true positive 
rate (Sensitivity) and true negative rate (Specificity) and AUC metric on CGC and nCan genes. b) 
OncoScore density score distribution of true positives and true negatives. The blue line represents the 
CGC and the grey one the nCan genes. The dashed red line shows the optimal Youden’s cut-off 
threshold. 
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Fig. 3. Boxplot reporting the OncoScore values of all the genes carrying somatic mutations in chronic 
phase or blast crisis chronic myeloid leukemia samples. P-value = 0.0007 (Two-tailed Mann-Whitney 
test). 
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Fig. 4. Time-series OncoScore plot spanning from 1975 to 2016. A) Time-series plot involving a set of 
manually defined cancer (TP53, KRAS, NRAS, HRAS, ASXL1, IDH1, IDH2, TET2 and SETBP1) and 
housekeeping genes (GAPDH and GUSB). The grey boxes highlight two major scientific 
breakthroughs occurred during this time span. B) Time-series plot of 10 genes randomly selected from 
the CGC (ARID1A, HMGA2, KIF5B, NUP214, RBM15; dashed lines) and nCan (ALMS1, DCAF17, 
GPD1L, WFS1, RBM10; continuous lines) dataset. 
 
 




